5830418K08Rik Inhibitors

Chemicals classified as Cep295 Inhibitors are not directly targeting Cep295 but rather influence cellular processes and structures that are integral to Cep295's function within the cell. Cep295 is known to be involved in the proper functioning of the centrosome, a critical cellular structure for microtubule organization and cell cycle progression. The listed compounds affect the stability and dynamics of microtubules or the regulation of cell cycle progression, which are processes that Cep295 is indirectly associated with.

Microtubule-targeting agents such as Nocodazole, Paclitaxel, Vinblastine, and Colchicine affect microtubule polymerization and stability, which are crucial for centrosome function and can impact the role of Cep295 in centrosome cohesion. Cyclin-dependent kinase inhibitors like Roscovitine and Purvalanol A, as well as spindle poisons such as Griseofulvin, Monastrol, and S-trityl-L-cysteine, alter the dynamics of cell cycle progression and mitotic spindle formation, which can indirectly affect Cep295 function in centrosome duplication and separation. Plk1 and Aurora kinase inhibitors, BI 2536 and ZM447439, target enzymes that are essential for centrosome maturation and separation, processes that are associated with the function of Cep295. Dimethylenastron, another Eg5 kinesin inhibitor, can lead to defects in centrosome dynamics, further influencing Cep295 activity.